Table 5 Cost, utility, and discount rate input.
Parameter | Values | Source/assumption | OWSA | |
---|---|---|---|---|
Lower | Upper | |||
Drug costs per month (¥) | ||||
LAMA + LABA | ¥642 | IQVIA CHPA 2018 | ¥513 | ¥770 |
LABA + ICS | ¥114 | IQVIA CHPA 2018 | ¥91 | ¥136 |
LABA alone | ¥124 | IQVIA CHPA 2018 | ¥99 | ¥149 |
LAMA alone | ¥253 | IQVIA CHPA 2018 | ¥202 | ¥303 |
LABA + LAMA + ICS | ¥366 | IQVIA CHPA 2018 | ¥292 | ¥439 |
Cost of COPD maintenance (oxygen inhalation, expectorant, etc) per month (¥) | ||||
Mild COPD | ¥23 | ¥18 | ¥27 | |
Moderate COPD | ¥67 | ¥54 | ¥81 | |
Severe/very severe COPD | ¥187 | ¥150 | ¥225 | |
Cost of CB treatment per month (¥) | ¥288 | IQVIA CHPA 2018 | ¥100 | ¥500 |
Amoxicillin | ¥10 | IQVIA CHPA 2018 | – | – |
Dextromethorphan | ¥27 | IQVIA CHPA 2018 | – | – |
Ambroxol hydrochloride | ¥224 | IQVIA CHPA 2018 | – | – |
Aminophylline | ¥20 | IQVIA CHPA 2018 | – | – |
Ipratropium bromide | ¥7 | IQVIA CHPA 2018 | – | – |
AE costs (¥) | ||||
Exacerbation treated in inpatient | ||||
Mild COPD | ¥8,639 | ¥6,911 | ¥10,366 | |
Moderate COPD | ¥17,277 | ¥13,822 | ¥20,732 | |
Severe/very severe COPD | ¥25,915 | ¥20,732 | ¥31,099 | |
Exacerbation treated in outpatient | ¥395 | ¥316 | ¥474 | |
Cost of pneumonia | ¥32,394 | ¥25,916 | ¥38,873 | |
Screening and diagnosis costs (¥) | ||||
Cost of portable spirometer screening | ¥34 | Supplementary Table 9 | ¥27 | ¥41 |
Cost of questionnaire screening | ¥8 | Supplementary Table 9 | ¥6 | ¥9 |
Cost of additional tests to confirm COPD | ¥220 | Supplementary Table 8 | ¥176 | ¥264 |
Utility | ||||
Mild COPD | 0.81 | – | 0.65 | 0.97 |
Moderate COPD | 0.72 | 0.58 | 0.86 | |
Severe/very severe COPD | 0.67 | 0.54 | 0.80 | |
Correction for exacerbation in outpatient | 0.85 | 0.68 | 0.99 | |
Correction for exacerbation in inpatient | 0.50 | 0.40 | 0.60 | |
Correction for serious pneumonia | 0.50 | 0.40 | 0.60 | |
Discount rate | ||||
Effect | 3.5% | 0.00 | 5.00 | |
Costs | 3.5% | 0.00 | 5.00 |